Filing Details
- Accession Number:
- 0001562180-24-006947
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-09-24 20:25:46
- Reporting Period:
- 2024-09-20
- Accepted Time:
- 2024-09-24 20:25:46
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1710072 | Edgewise Therapeutics Inc. | EWTX | Pharmaceutical Preparations (2834) | 821725586 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1853529 | J Alan Russell | C/O Edgewise Therapeutics, Inc. 1715 38Th Street Boulder CO 80301 | Chief Scientific Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-09-20 | 75,000 | $0.18 | 87,719 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-09-20 | 74,185 | $28.25 | 13,534 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-09-20 | 815 | $29.51 | 12,719 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-09-20 | 75,000 | $0.00 | 75,000 | $0.18 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 1,456,780 | 2032-06-27 | No | 4 | M | Direct |
Footnotes
- Includes 2,968 shares purchased on May 15, 2023, 2,088 shares purchased on November 15, 2023 and 425 shares purchased on May 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
- The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $28.02 to $28.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $29.56, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 1/48th of the shares subject to the option vested each month beginning on June 27, 2017.
Billionaire Hedge Funds
